Deep, rapid, and durable prostate-specific antigen decline with apalutamide plus androgen deprivation therapy is associated with longer survival and improved clinical outcomes in TITAN patients with metastatic castration-sensitive prostate cancer ☆
Title:
Deep, rapid, and durable prostate-specific antigen decline with apalutamide plus androgen deprivation therapy is associated with longer survival and improved clinical outcomes in TITAN patients with metastatic castration-sensitive prostate cancer ☆
Author:
Chowdhury, S. Bjartell, A. Agarwal, N. Chung, B.H. Given, R.W. Pereira de Santana Gomes, A.J. Merseburger, A.S. Özgüroğlu, M. Juárez Soto, Á. Uemura, H. Ye, D. Brookman-May, S.D. Londhe, A. Bhaumik, A. Mundle, S.D. Larsen, J.S. McCarthy, S.A. Chi, K.N.